April 2018 in “Journal of Investigative Dermatology” This study suggests that for dermatomyositis patients with minimal skin disease activity, further improvement in cutaneous symptoms may not translate into better quality of life, highlighting a need to revise trial endpoints.
2 citations
,
January 2006 in “Technical report” This chapter reviews the development of skin-specific outcome instruments for autoimmune diseases like cutaneous lupus erythematosus and dermatomyositis, highlighting a need for a broader community-involved process across other diseases but reports no new results.
January 2002 in “대한피부과학회지” This study analyzed clinical manifestations in 18 dermatomyositis patients, noting that all exhibited skin rash and variable symptoms like itching and muscle weakness, with treatment involving prednisolone and hydroxychloroquine.
June 2024 in “British Journal of Dermatology” In this prospective observational study of 96 dermatomyositis patients, 47 showed scalp involvement, with significant symptoms like scalp inflammation, itching, and hair loss linked to myositis-specific antibodies. The study highlighted unique dermatopathological features in the scalp and emphasized the considerable morbidity caused by scalp dermatomyositis.
3 citations
,
March 2002 in “Linchuang pifuke zazhi” This study analyzed clinical manifestations of dermatomyositis in 18 patients, reporting common symptoms such as skin rash, proximal muscle weakness, and elevated serum markers, with treatment typically involving prednisolone and hydroxychloroquine.
